$MBRXJun 5, 2026, 8:29 AM ETAI processed
Survey shows strong physician intent to prescribe Moleculin's Annamycin in R/R AML
AI Summary
Independent market research found hematologist‐oncologists gave Annamycin an average likelihood‐to‐prescribe score of 6/7 in relapsed/refractory AML, citing reported deep and MRD‐negative remissions, transplant‐bridging potential, biomarker‐agnostic use and reduced cardiotoxicity as adoption drivers. Payers interviewed also viewed the drug's efficacy/safety profile and broad applicability favorably; the study is qualitative and directional (not predictive), no new clinical efficacy data were released, and Annamycin is advancing in a pivotal adaptive Phase 2b/3 (MIRACLE) trial following prior Phase 1B/2 results.
Positives
- Physician average likelihood‑to‑prescribe score of 6 out of 7 for Annamycin in R/R AML
- Payers indicated efficacy, safety and broad applicability could support a compelling value proposition
- Annamycin is positioned as non‑cardiotoxic and transplant‑bridging, and is advancing in a Phase 2b/3 pivotal trial after Phase 1B/2
Negatives
- Study is a small, qualitative market assessment and is directional rather than statistically predictive
- No new clinical trial readout or randomized efficacy data were reported in this announcement
- Company states it will require significant additional financing and has no committed funding disclosed